MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 10-31-2025
Merus N.V. Cash Conversion Cycle 2011-2026 | MRUS
Annual Cash Conversion Cycle Merus N.V.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 18.6 | 26.9 | 25.2 | 6.48 | 6.02 | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 26.9 | 6.02 | 16.7 |
Quarterly Cash Conversion Cycle Merus N.V.
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 135 | 161 | 26.6 | - | 11.5 | 377 | 354 | - | 25.9 | 33.1 | 29.8 | - | 45.2 | 23.6 | 17.1 | - | 10.4 | 6.51 | 1.86 | - | 0.49 | 0.69 | 7.15 | - | 10.5 | 13.5 | 6.77 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 377 | 0.49 | 61.8 |
Cash Conversion Cycle of other stocks in the Biotechnology industry
| Issuer | Cash Conversion Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
3.11 K | - | 5743.5 % | $ 69.7 M |  Canada |
 |
Happiness Biotech Group Limited
HAPP
|
-3.12 K | - | 1.35 % | $ 17.8 M |  China |
 |
AgeX Therapeutics
AGE
|
186 | - | -10.17 % | $ 12.2 K |  USA |
 |
I-Mab
IMAB
|
-1.97 K | - | - | $ 866 M | China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
12.8 | - | - | $ 40.3 B | USA |
 |
AstraZeneca PLC
AZN
|
-58 | - | - | $ 96.9 B |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
17 | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
82.8 | - | -18.52 % | $ 27.3 M | Britain |
 |
Институт стволовых клеток человека
ISKJ
|
104 | - | - | - |  Russia |
 |
Celyad Oncology SA
CYAD
|
-55.7 K | - | - | $ 12.5 M |  Belgium |
 |
Berkeley Lights
BLI
|
214 | - | -7.31 % | $ 87 M | USA |
 |
Generation Bio Co.
GBIO
|
47.6 | - | - | $ 344 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
119 | $ 1.65 | 1.85 % | $ 439 M | Britain |
 |
Ayala Pharmaceuticals
AYLA
|
-2.15 K | - | - | $ 7.46 M |  Israel |
 |
Cyclacel Pharmaceuticals
CYCCP
|
-1.6 K | - | -4.36 % | $ 27 M | USA |
 |
Compugen Ltd.
CGEN
|
-82.7 | $ 2.61 | -3.51 % | $ 244 M | Israel |
 |
Anika Therapeutics
ANIK
|
192 | $ 15.02 | -0.79 % | $ 215 M | USA |
 |
Advaxis
ADXS
|
-82.3 K | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
-34.3 K | - | 5.93 % | $ 314 M | Canada |
 |
Applied Genetic Technologies Corporation
AGTC
|
126 | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
-1.92 | - | 1.93 % | $ 17.4 M | USA |
 |
Aptinyx
APTX
|
46.9 | - | -39.0 % | $ 4.57 M | USA |
 |
Coherus BioSciences
CHRS
|
149 | $ 1.57 | 3.97 % | $ 184 M | USA |
 |
Albireo Pharma
ALBO
|
-1.55 K | - | -0.23 % | $ 916 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
158 | $ 21.01 | 2.64 % | $ 2.67 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-4.62 K | - | -11.43 % | $ 502 K | USA |
 |
Alpine Immune Sciences
ALPN
|
154 | - | - | $ 2.17 B | USA |
 |
Aravive
ARAV
|
16.8 | - | -13.39 % | $ 1.45 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
59 | - | 17.91 % | $ 11.1 M | USA |